KIN1148 - IRF3 Agonist - MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEKIN1148Cat. No.: HY-101950CAS No.: 1428729-56-9分式: CHNOS分量: 361.44作靶點(diǎn): Influenza Virus作通路: Anti-infection儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 100 mg/mL (276.67 mM)* means soluble

2、, but saturation unknown.Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 2.7667 mL 13.8336 mL 27.6671 mL5 mM 0.5533 mL 2.7667 mL 5.5334 mL10 mM 0.2767 mL 1.3834 mL 2.7667 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請(qǐng)注意儲(chǔ)備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 KIN1148種分 IRF3 激動(dòng)劑，作增強(qiáng)流感疫苗效率的佐劑。體外研究 KIN1148 induces the

3、dose-dependent nuclear translocation of IRF3 in PH5CH8 cells and specific activationof IRF3- responsive promoters. KIN1148 also elicits greater induction of endogenous IRF3-dependent ISG54and OASL expression by PH5CH8 cells 1.1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE體內(nèi)研究 Prime-boost immuniza

4、tion of mice with a suboptimal dose of a monovalent pandemic influenza split virusH1N1 A/California/07/2009 vaccine plus KIN1148 protect against a lethal challenge with mouse-adaptedinfluenza virus (A/California/04/2009) and induce an influenza virusspecific IL-10 and Th2 response by Tcells derived

5、from lung and lung-draining lymph nodes. Primeboost immunization with vaccine plus KIN1148,but not prime immunization alone, induce antibodies capable of inhibiting influenza virus hemagglutinin andneutralizing viral infectivity. Nevertheless, a single immunization with vaccine plus KIN1148 providei

6、ncreased protection over vaccine alone and reduce viral load in the lungs after challenge 1.PROTOCOLAnimal Mice: The final liposomes prior to mixing with vaccine contained KIN1148 (5 mg/mL) and phospholipids (40Administration 1 mg/mL) and are delivered intramuscularly (KIN1148 at 50 g and phospholip

7、id at 400 g per dose). Blankliposomes are prepared without KIN1148 as vehicle control. KIN1148 liposome and blank liposomeformulations are stable for at least 4 months at 4C and are used for in vivo experiments within a month afterpreparation 1.MCE has not independently confirmed the accuracy of the

8、se methods. They are for reference only.REFERENCES1. Probst P, et al. A small-molecule IRF3 agonist functions as an influenza vaccine adjuvant by modulating the antiviral immune response.Vaccine. 2017 Apr 4;35(15):1964-1971.McePdfHeightCaution: Product has not been fully validated for medical applications.For